Hanmi Pharm. Co., Ltd. (KRX:128940)

South Korea · Delayed Price · Currency is KRW

417,000

+19,500 (4.91%)

Jul 1, 2026, 2:00 PM KST

44.04% (1Y)

Market Cap	5.04T +32.9%
Revenue (ttm)	1.55T +4.5%
Net Income	172.44B +58.3%
EPS	13,587.63 +58.2%
Shares Out	12.68M
PE Ratio	29.25
Forward PE	25.99
Dividend	1,250.00 (0.29%)
Ex-Dividend Date	Mar 30, 2026

Volume	78,271
Open	404,500
Previous Close	397,500
Day's Range	386,500 - 421,500
52-Week Range	267,500 - 647,000
Beta	0.44
Analysts	Buy
Price Target	624,615.38 (+49.79%)
Earnings Date	Jul 29, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1973

Employees 2,400

Stock Exchange Korea Stock Exchange

Ticker Symbol 128940

Full Company Profile

Financial Performance

In 2025, Hanmi Pharm.'s revenue was 1.55 trillion, an increase of 3.48% compared to the previous year's 1.50 trillion. Earnings were 169.55 billion, an increase of 39.76%.

Financial Statements

Analyst Summary

According to 13 analysts, the average rating for 128940 stock is "Buy." The 12-month stock price target is ₩624,615, which is an increase of 49.79% from the latest price.

Price Target

₩624,615

(49.79% upside)

Analyst Consensus: Buy

Stock Forecasts